AirBoss Manufactured Products’ (“AMP”) defense business awarded a contract from the U.S. Government valued at up to $82.3M for ADG Molded Lightweight Overboots (“MALOs”); AirBoss Rubber Solutions ...

Black Diamond Group Limited ("Black Diamond", the "Company" or "we"), , a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results ...

AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) (the "Company" or "AirBoss") today announced its unaudited fourth quarter and annual 2024 results.

In a significant shift, the Ugandan government has announced major changes to the A’level curriculum, impacting 29 subjects. Teachers will now focus on entire subjects rather than individual papers, ...

Creating battery electrolytes—the component that carries the charged particles back and forth between a battery's two ...

Scientists have discovered 'berkelocene,' the first organometallic molecule to be characterized containing the heavy element berkelium. The breakthrough disrupts long-held theories about the chemistry ...

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply. Eli Lilly, the maker of Zepbound and Mounjaro, and Novo ...

BLK wraps up the acquisition of Preqin. Will Preqin and other strategic buyouts help drive the company's financials going ...

The company has a proven model combining organic and inorganic growth. This compounder could grow for years, if not decades. There are many methods investors can employ, including value investing ...

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns. Companies such as ...

APhA, in a formal comment letter, reiterated its concerns with FDA's list of drugs that present ... identified as "demonstrably difficult to compound" without becoming a manufacturer.